6.1.2025 15:00:27 CET | Thor Medical ASA | Flagging

Oslo, Norway, 6 January 2025: Reference is made to the stock exchange
announcements by Thor Medical ASA (the "Company") on 11 December 2024 regarding
a private placement of new shares to be issued by the Company (the "Private
Placement") and stock exchange announcement on 6 January 2025 regarding the
completion of an extraordinary general meeting.

The extraordinary general meeting resolved to issue the 23,396,380 new shares
(the "Offer Shares") in tranche 2 ("Tranche 2") of the Company's completed
Private Placement. As part of the settlement arrangements for the Private
Placement, the Company has entered into a share lending agreement (the "Share
Lending Agreement") with Carnegie AS (the "Manager") and Scatec Innovation AS.

Under the Share Lending Agreement, Scatec Innovation AS has agreed to lend
existing and unencumbered shares in the Company, already being traded on
Euronext Oslo Børs, to the Manager for the settlement of Tranche 2 of the
Private Placement. The borrowed shares will be used for settlement towards
investors having been allocated Offer Shares in Tranche 2 of the Private
Placement. The Offer Shares will be subscribed for by the Manager and, once
issued, delivered to Scatec Innovation AS as redelivery of the shares borrowed
for the purpose of the settlement of Tranche 2 of the Private Placement.

Prior to the completion of Tranche 2 of the Private Placement, Scatec Innovation
AS held 66,002,256 shares in the Company, representing approx. 23.5% of the
issued share capital and votes. Scatec Innovation AS has lent a total of
11,396,380 existing shares which will be delivered to the investors in Tranche 2
of the Private Placement other than Scatec Innovation AS. During the term of the
loan, and prior to the redelivery, Scatec Innovation AS' shareholding in the
Company will be reduced to 54,605,876, equivalent to approx. 19.5% of the issued
share capital and votes. Consequently, Scatec Innovation AS has fallen below the
20% threshold pursuant to section 4-2 (1) and (3) of the Norwegian Securities
Trading Act.

In addition, Scatec Innovation AS has controlling interest in Scatec Invest IV
AS, which holds 3,165,920 shares in the Company. Scatec Innovation AS aggregated
shareholding is thus 57,771,796 after the share lending, equivalent to approx.
20.6% of the issued share capital and votes in the Company.

This announcement is published in accordance with section 4-2 of the Norwegian
Securities Trading Act and is subject to disclosure requirements pursuant to the
EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading
Act section and 5-12.

 

Contacts

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, 
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - http://www.thormedical.no - 
https://www.thormedical.no.

 

VEDLEGG

Last ned som PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18375244/5505/Last%20ned%20som%20
PDF.pdf

Primary insider notification.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18375244/5504/Primary%20insider%2
0notification.pdf